Cenestin

moderate Vulvovaginal atrophy, Hot flashes, Menopause + 2 more

Treatment

5 FDA approvals

19 Active Studies for Cenestin

What is Cenestin

Synthetic Conjugated Estrogens, A

The Generic name of this drug

Treatment Summary

Synthetic conjugated estrogens A is a medication designed to mimic the effects of hormones in the body. It is used to treat menopause-related symptoms, such as hot flashes, painful intercourse, and vaginal dryness. The medication is made of nine synthetic estrogenic substances derived from plants, such as yam or soy plants. This drug is not to be confused with Conjugated Equine Estrogens (CEEs), which is derived from the urine of pregnant mares and contains a blend of at least 10 estrogen derivatives. Synthetic conjugated estrogens A is marketed under the brand name Enjuvia.

Cenestin

is the brand name

Cenestin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cenestin

Synthetic Conjugated Estrogens, A

1999

8

Approved as Treatment by the FDA

Synthetic Conjugated Estrogens, A, also known as Cenestin, is approved by the FDA for 5 uses which include moderate Menopausal Vasomotor Symptoms and Hot flashes .

moderate Menopausal Vasomotor Symptoms

Helps manage moderate Menopausal Vasomotor Symptoms

Hot flashes

Helps manage Menopause

Menopause

Helps manage severe Vasomotor Symptoms Associated With Menopause

severe menopausal vulvovaginal atrophy

Helps manage severe menopausal vulvovaginal atrophy

moderate Vulvovaginal atrophy

Helps manage moderate Vulvovaginal atrophy

Effectiveness

How Cenestin works in the body

Estrogen is a hormone that is responsible for the development and maintenance of the female reproductive system. Before menopause, it is produced in the ovaries. After menopause, the production of estrogen drops off significantly, leading to a variety of symptoms. These symptoms can be reduced through Hormone Replacement Therapy (HRT), which replaces estrogen lost during and after menopause with either synthetic or naturally occurring hormones.

When to interrupt dosage

The recommended measure of Cenestin is contingent upon the identified condition, such as Menopause, moderate Menopausal Vasomotor Symptoms and serious menopausal vulvovaginal atrophy. The dosage is contingent upon the method of administration, as outlined in the table below.

Condition

Dosage

Administration

Hot flashes

, 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, 0.45 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral

moderate Menopausal Vasomotor Symptoms

, 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, 0.45 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral

moderate Vulvovaginal atrophy

, 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, 0.45 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral

severe menopausal vulvovaginal atrophy

, 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, 0.45 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral

Menopause

, 0.3 mg, 0.625 mg, 0.9 mg, 1.25 mg, 0.45 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Cenestin has ten contraindications and should not be employed while enduring the conditions in the below table.

Cenestin Contraindications

Condition

Risk Level

Notes

Thromboembolism

Do Not Combine

Liver Dysfunction

Do Not Combine

Breast Cancer

Do Not Combine

Venous Thrombosis

Do Not Combine

Breast

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Pulmonary Embolism

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Pulmonary Embolism

Do Not Combine

There are 20 known major drug interactions with Cenestin.

Common Cenestin Drug Interactions

Drug Name

Risk Level

Description

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Synthetic Conjugated Estrogens, A.

Dasabuvir

Major

The risk or severity of liver enzyme elevations can be increased when Synthetic Conjugated Estrogens, A is combined with Dasabuvir.

Exemestane

Major

The therapeutic efficacy of Exemestane can be decreased when used in combination with Synthetic Conjugated Estrogens, A.

Ombitasvir

Major

The risk or severity of liver enzyme elevations can be increased when Synthetic Conjugated Estrogens, A is combined with Ombitasvir.

Ospemifene

Major

The risk or severity of adverse effects can be increased when Synthetic Conjugated Estrogens, A is combined with Ospemifene.

Cenestin Novel Uses: Which Conditions Have a Clinical Trial Featuring Cenestin?

16 active trials are investigating the efficacy of Cenestin in mitigating symptoms associated with Menopause, moderate Menopausal Vasomotor Symptoms and Menopause-related disorders.

Condition

Clinical Trials

Trial Phases

moderate Vulvovaginal atrophy

0 Actively Recruiting

moderate Menopausal Vasomotor Symptoms

0 Actively Recruiting

Menopause

0 Actively Recruiting

severe menopausal vulvovaginal atrophy

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

Cenestin Reviews: What are patients saying about Cenestin?

5

Patient Review

6/4/2014

Cenestin for "Change of Life" Signs

Despite what you may have heard, Cenestin has not been discontinued. I called the manufacturer today and they said that while the 1.25 mg tablets are unavailable at the moment, the smaller dosage tablets (.3 and .45 mg) are still available.

5

Patient Review

1/22/2015

Cenestin for "Change of Life" Signs

I had been taking Cenestin for 13 years with great results. Then I could not get it anymore and I was put on Premarin. After only a few weeks my hair was falling out, brittle nails, 7/24 heartburn so I had to take Prilosec. I stopped the Premarin and now have hot flashes all the time. Wish they would bring it back again.

5

Patient Review

8/23/2014

Cenestin for "Change of Life" Signs

I've been taking this medication for over a decade and it's really helped me. I don't have any of the negative side effects that come with menopause, and I'm thankful for that. However, when I was switched to Premarin 1.25, it was like taking no medication at all—my life turned upside down.

5

Patient Review

9/3/2014

Cenestin for "Change of Life" Signs

I've used Cenestin .625 for almost 20 years and it's been amazing. I'm so upset that Teva is no longer making it. Hopefully there's another medication out there that can give me the same results.

5

Patient Review

8/10/2013

Cenestin for "Change of Life" Signs

Cenestin is extremely effective for me, but the price is quite high. It was the only medication I tried that had no negative side effects and actually made me feel better than normal.

5

Patient Review

7/13/2015

Cenestin for "Change of Life" Signs

Cenestin was really the best medication I tried after my hysterectomy in 2004. It alleviated hot flashes, night sweats, and overall made me feel great. Unfortunately, the company stopped making it and I haven't been able to find anything that comes close to working as well since then.

5

Patient Review

10/25/2017

Cenestin for "Change of Life" Signs

I haven't been able to find Cenestin recently, is it no longer being made? When I took it before I always felt much better.

5

Patient Review

4/13/2011

Cenestin for "Change of Life" Signs

5

Patient Review

10/11/2011

Cenestin for "Change of Life" Signs

5

Patient Review

2/2/2012

Cenestin for "Change of Life" Signs

I had a hysterectomy 15 years ago and have been on Cenestin since. I just recently stopped taking them,I was concerned about the length of time I have been on them and things have been horrible since I stopped, nite sweats,hot flashes,mood swings and NO desire. I'm ready to go back to taking them again. It worked wonders for me!

4

Patient Review

3/21/2014

Cenestin for "Change of Life" Signs

I've been taking Cenestin for years with great results, but now that it's been discontinued I have to switch to something else. Not happy about it!!!

4

Patient Review

12/30/2011

Cenestin for "Change of Life" Signs

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cenestin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Cenestin?

"The side effects of birth control pills can include: nausea, vomiting, bloating, stomach cramps, breast tenderness/pain/swelling, headache, changes in weight or appetite, and freckles or darkening of facial skin."

Answered by AI

Do they still make Cenestin?

"The Cenestin brand of medication has been discontinued in the United States. However, if generic versions of this product have been approved by the U.S. Food and Drug Administration (FDA), there may be generic equivalents of Cenestin available."

Answered by AI

What is Cenestin used for?

"This medication is a female hormone that is used to help reduce symptoms of menopause. The symptoms are caused by the body making less estrogen."

Answered by AI

What is Cenestin made of?

"Cenestin, a medication made from soy and yam plants, will be available to prescribe within 90 days in two dosages--0.625 mg and 0.9 mg."

Answered by AI

Clinical Trials for Cenestin

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada

The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.

Phase 4
Recruiting

Erevna Innovations Inc.

Andreas Nikolis, MD, PhD

Have you considered Cenestin clinical trials?

We made a collection of clinical trials featuring Cenestin, we think they might fit your search criteria.
Go to Trials
Image of Noll Laboratory in University Park, United States.

Estradiol and Elagolix for Menopause

42 - 64
Female
University Park, PA

The frequency and severity of heat waves has increased in the last decades. Older adults (over 65 years) have impaired responses to heat stress making them at increased risk for adverse events. Previous heat waves report that women over 65 experience worse health outcomes than any other age group and age matched men. Aging and reproductive hormones, specifically estrogen, independently alter responses to heat stress. However, the combined effects of low estrogen following menopause and aging on the response to heat stress are unknown. In this study, the investigators will identify the role of estrogen in pre and post menopausal women on thermoregulatory responses to heat stress.

Phase 4
Recruiting

Noll Laboratory

W. Larry Kenney, Ph.D.

Have you considered Cenestin clinical trials?

We made a collection of clinical trials featuring Cenestin, we think they might fit your search criteria.
Go to Trials
Image of Rehabilitation R&D Service, Baltimore, MD in Baltimore, United States.

Cognitive Behavioral Therapy for Menopause

18+
Female
Baltimore, MD

Women are the fastest-growing group of U.S. Veterans. Over half of those using VA care are 45 or older, with more age-related health concerns than civilian women. The VA urgently needs gender-informed strategies to ensure women Veterans receive tailored care that addresses their intersecting mental, physical, and age related health concerns, as well as gender-linked stressors. One prominent example is menopause, a health transition period that, for many women, can be associated with negative physical and mental health concerns that can worsen their functioning and quality of life. This project will: (1) integrate stakeholder feedback to tailor Cognitive Behavioral Therapy for Menopause (CBT-Meno) for women Veterans with menopause concerns; and (2) refine and evaluate tailored CBT-Meno as a treatment to address these intersecting needs in a clinical trial.

Waitlist Available
Has No Placebo

Rehabilitation R&D Service, Baltimore, MD (+2 Sites)

Haley Miles-McLean, PhD

Image of Student Health and Wellness Building - Department of Kinesiology in Charlottesville, United States.

Nitrate Supplementation and Exercise for Menopause

45 - 75
Female
Charlottesville, VA

Menopause greatly increases cardiovascular disease risk (CVD). Current exercise guidelines are inadequate to ameliorate this risk and higher intensity exercise may be necessary for cardiovascular benefits in postmenopausal females. Oral nitrate supplementation enhances exercise performance and CVD risk profile in several clinical conditions. The investigators recently reported that 3-days of nitrate supplementation in postmenopausal females enhances acute post-exercise vascular function, in an intensity dependent manner. The effects of nitrate supplementation and exercise training over a longer training program remains unexplored. This investigation will examine the impact of exercise training intensity with and without inorganic nitrate supplementation, on CVD and fitness outcomes. Postmenopausal females will be tested for maximal oxygen uptake and lactate threshold before randomization to one of four groups: that inorganic nitrate-rich beetroot juice, or beetroot juice with nitrate extracted; and assigned to one-month of calorie matched high-intensity or moderate-intensity exercise training. Vascular function and fitness will be evaluated before and after training.

Recruiting
Paid Trial

Student Health and Wellness Building - Department of Kinesiology

Jason Allen, PhD

Image of University of Colorado Anschutz Medical Campus in Aurora, United States.

Estradiol Patch for Menopause

20 - 45
Female
Aurora, CO

The menopause transition is associated with a decrease in artery health and an increased risk for weight gain in storing fat in the stomach area which may increase the risk for heart disease. The purpose of this research is to study how the decrease in estrogen at menopause changes artery health and fat gain, and risk of disease in women as they age. The first aim in this study will determine whether short term and long term low estrogen levels in premenopausal women decreases artery function and whether this is related to an increase in fat in the stomach area. The second aim will determine whether the changes in artery health and body fat are related to changes in a pathway that breaks down an important amino acid called tryptophan. This pathway is thought to play a role in regulating the aging process. Therefore, the investigators will determine whether the decrease in artery health and the increase in body fat in the stomach region with low estrogen is related to changes in this pathway in the blood, in vascular cells and fat tissue. Because estrogen levels fluctuate in premenopausal women, the investigators will use an approach (intervention) that controls estrogen levels to address these aims. The investigators will use a medication that is typically used to treat endometriosis or uterine fibroids to lower estrogen levels and an estrogen patch to increase estrogen in some women. Some women will receive a patch that has no estrogen (called a placebo patch). The intervention period will be 20 weeks. The study will provide us with new knowledge on how low estrogen with menopause affects artery health and fat gain estrogen.

Phase 4
Recruiting

University of Colorado Anschutz Medical Campus

Kerrie Moreau, PhD

Have you considered Cenestin clinical trials?

We made a collection of clinical trials featuring Cenestin, we think they might fit your search criteria.
Go to Trials